Eye diseases often develop asymptomatically for many years. ICTER scientists have developed the f-ORG technique, which ...

Privately-held Ashvattha Therapeutics, a Californian firm advancing a new class of nanomedicine therapeutics that traverse ...

While it is easier to advise people to not sit for long hours in front of their screens, for those who work on a computer, it is a difficult task to achieve. Sitting for a prolonged time in front of ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an ...

Age-related macular degeneration (AMD) AMD is a common eye condition that happens as you get older. It affects the macula, ...

Ocular Therapeutix (NASDAQ:OCUL) stock rises as Needham rates the company a new Buy, citing the potential of its lead candidate, Axpaxli. Read more here.

Certified AI management practitioner and AI strategy advisor at Techstars Jess Jeetley, who was once a practising optometrist, discusses how AI could be integrated into healthcare ...

Fintel reports that on March 11, 2025, Needham initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Buy ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. <li /> GLOW2 study design mirrors GLOW1 study, ...

Professor Yit Yang discussed how pathology identified in retinal layers after an OCT scan can lead to diagnosis in his ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be ...